A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

• Main Authors: Kevin L. Russell (Author), Richard E. Rupp (Author), Javier O. Morales-Ramirez (Author), Clemente Diaz-Perez (Author), Charles P. Andrews (Author), Andrew W. Lee (Author), Tyler S. Finn (Author), Kara S. Cox (Author), Amy Falk Russell (Author), Margaret M. Schaller (Author), Jason C. Martin (Author), Donna M. Hyatt (Author), Sabrina Gozlan-Kelner (Author), Androniki Bili (Author), Beth-Ann G. Coller (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. V181 is an investigational, live, attenuated, quadrivalent dengue vaccine. In this phase 1 double-blind, placebo-controlled study, the safety, tolerability, and immu...